Chemotherapy without or with radiation remains the best for many cancers. However, intolerant negative effects and traditional drug resistance restrict actual clinical effectiveness. Curaxin CBL0137 is made to regulate p53 and nuclear factor-|¨ºB concurrently and also to avoid the resistance the result of a single target. Functionally, CBL0137 exhibits an antitumor activity in multiple cancers, including glioblastoma, kidney cell carcinoma, melanoma, neuroblastoma, and small cell cancer of the lung (SCLC). Mechanistically, CBL0137 is initially identified to do something by facilitates chromatin transcription (FACT) complex. Further investigations demonstrate that several pathways, for example NOTCH1 as well as heat shock factor 1 (HSF1), take part in the procedure. CBL0137 continues to be reported to focus on cancer stem cells (CSCs) and enhance chemotherapy/monotherapy effectiveness. The translational coming of CBL0137 into clinical practice is anticipated to supply a promising future for cancer treatment.